Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bioorganic chemistry (Print)

• Publication date

  2014-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bioorg.2014.05.010PMID 24922538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

  2012cited by this paper
• Design and synthesis of small molecule RhoA inhibitors: a new promising therapy for cardiovascular diseases?

  2011cited by this paper
• Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.

  2011cited by this paper
• Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

  2011cited by this paper
• Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.

  2010cited by this paper
• Vascular endothelial growth factor receptor-2 in breast cancer.

  2010cited by this paper
• The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

  2010cited by this paper
• Signal transduction therapy of cancer.

  2010cited by this paper
• p‐Nitrobenzazide and p‐nitrophenyl isocyanate as reagents for the identification of amines

  2010cited by this paper
• Amide bond formation: beyond the myth of coupling reagents.

  2009cited by this paper
• Synthesis of 2,3‐dichloroquinoxalines via Vilsmeier reagent chlorination

  2009cited by this paper
• New bis(2-aminoimidazoline) and bisguanidine DNA minor groove binders with potent in vivo antitrypanosomal and antiplasmodial activity.

  2008cited by this paper
• Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: evaluation of in vitro anti-cancer and anti-folate activities.

  2008cited by this paper
• Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives.

  2007cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Inhibitors of signal transduction protein kinases as targets for cancer therapy.

  2006cited by this paper
• Strong protective action of Copper(II) N-substituted sulfonamide complexes against reactive oxygen species.

  2004cited by this paper
• Su-11248 Sugen.

  2004cited by this paper
• Tyrosine kinase inhibitors in cancer therapy.

  2004cited by this paper
• Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

  2004cited by this paper
• Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding.

  2004cited by this paper
• Tyrosine kinase receptors as attractive targets of cancer therapy.

  2004cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.

  2003cited by this paper
• Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

  2002cited by this paper
• Design and discovery of small molecules targeting raf-1 kinase.

  2002cited by this paper
• Imatinib: a selective tyrosine kinase inhibitor.

  2002cited by this paper
• New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

  2000cited by this paper
• New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

  2000cited by this paper
• Regioselective substitution of 2,3-dichloro-6-amino-quinoxaline

  2000cited by this paper
• Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

  1999cited by this paper
• Development and validation of a genetic algorithm for flexible docking.

  1997cited by this paper
• Kinetic study on the anelation of heterocycles. 1. Quinoxalinone derivatives synthesized by hinsberg reaction

  1987cited by this paper
• Quinoxalines and related compounds—XI: The formation of fused pyrroles by the condensation of haloazines with methylazines

  1979cited by this paper
• 223. Quinoxalines and related compounds. Part VI. Substitution of 2,3-dihydroxyquinoxaline and its 1,4-dimethyl derivative

  1962cited by this paper
• Methoden der organischen Chemie (Houben-Weyl)

  1952cited by this paper

• New Benzimidazole Scaffolds Tagged With Isatin/Thiourea Motifs as Anti‐Cancer Agents: Promising Approach for VEGFR‐2 Inhibition

  2026cites this paper
• Contemporary trends on the kinase inhibitors with special reference to quinoxaline derivatives.

  2025cites this paper
• Evaluation of oxadiazole-N-phenylacetamide conjugates as VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative assessment, molecular docking, and dynamics studies.

  2025cites this paper
• Recent advances in photo-promoted generalized C3-H alkylation of quinoxalin-2(1H)-ones.

  2025cites this paper
• Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study

  2025cites this paper
• Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR/VEGFR-2 inhibition.

  2025cites this paper
• Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer

  2025cites this paper
• The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy.

  2024cites this paper
• Photocatalytic multi-component synthesis of ester-containing quinoxalin-2(1H)-ones using water as the hydrogen donor

  2024cites this paper
• Visible-light-induced tandem reaction of quinoxalin-2(1H)-ones, alkenes, and sulfonyl chlorides.

  2024cites this paper
• Visible-light-induced four-component difunctionalization of alkenes to construct phosphorodithioate-containing quinoxalin-2(1H)-ones

  2024cites this paper
• Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition.

  2024cites this paper
• Metal- and photocatalyst-free approach to visible-light-induced acylation of quinoxalinones.

  2024cites this paper
• Novel Thiazolidine‐2,4‐Dione Derivatives as Potential VEGFR‐2 Inhibitors: Synthesis, Biological Testing, and in Silico Studies

  2024cites this paper
• Synthesis of 1H-benzimidazoles via the condensation of o-phenylenediamines with DMF promoted by organic acid under microwave irradiation

  2024cites this paper
• New vatalanib analogs: design, synthesis, in silico study and biological evaluation for anticancer activity

  2024cites this paper
• Visible-light-mediated direct C3 alkylation of quinoxalin-2(1H)-ones using alkanes.

  2024cites this paper
• Challenging the anticolorectal cancer capacity of quinoxaline-based scaffold via triazole ligation unveiled new efficient dual VEGFR-2/MAO-B inhibitors.

  2024cites this paper
• Role of heterocycles in inhibition of VEGFR-2 - a recent update (2019-2022).

  2024cites this paper
• Revealing the contributions of DFT to the spectral interpretation for an amino benzoyl thiourea derivative: Insights into experimental studies from theoretical perspectives, and biological evaluation

  2023cites this paper
• Aerobic oxidative C-H phosphorylation of quinoxalines under catalyst-free conditions.

  2023cites this paper
• New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro, and in silico studies

  2023cites this paper
• Synthesis of novel antibacterial and antifungal quinoxaline derivatives

  2022cites this paper
• Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies

  2022cites this paper
• Recent Advances on Biological Active Sulfonamide based Hybrid Compounds Part B: Two-Component Sulfonamide Hybrids.

  2022cites this paper
• Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents

  2022influential citation
• DDDT_A_344750 587..606

  2022influential citation
• New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation

  2022influential citation
• Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.

  2022cites this paper
• Visible-light-induced decarboxylative alkylation of quinoxalin-2(1H)-ones with phenyliodine(III) dicarboxylates by cerium photocatalysis

  2022cites this paper
• Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.

  2022cites this paper
• Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2

  2022cites this paper
• Metal‐ And Light‐Free Direct C‐3 Ketoalkylation of Quinoxalin‐2(1 H )‐Ones with Cyclopropanols in Aqueous Medium

  2022cites this paper
• Targeting VEGFR‐2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies

  2021cites this paper
• Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.

  2021cites this paper
• New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.

  2021cites this paper
• Discovery of pyridine- sulfonamide hybrids as a new scaffold for the development of potential VEGFR-2 inhibitors and apoptosis inducers.

  2021cites this paper
• Metal‐, Photocatalyst‐, Light‐ and Electrochemical‐Free C‐3 Trifluoromethylation of Quinoxalin‐2(1 H )‐ones, Imidazo[1,2‐a]pyridines and 2 H ‐Indazoles

  2021cites this paper
• Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers

  2021cites this paper
• Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.

  2021cites this paper
• A visible-light photoredox-catalyzed four-component reaction for the construction of sulfone-containing quinoxalin-2(1H)-ones

  2021cites this paper
• Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase

  2021cites this paper
• Metal-free C3 α-aminoalkylation of quinoxalin-2(1H)-ones with amines

  2021cites this paper
• Recent Advances in Direct C−H Trifluoromethylation of N‐Heterocycles

  2021cites this paper
• Direct decarboxylative C H 3-arylation of quinoxalin-2(H)-ones with aryl acyl peroxides leading to 3-arylquinoxalin-2(1H)-ones

  2020cites this paper
• Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.

  2020cites this paper
• Visible-light induced phosphonation of quinoxalines and quinoxalin-2(1H)-ones under aerobic metal-free conditions

  2020cites this paper
• Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.

  2020cites this paper
• Electrochemical decarboxylative C3 alkylation of quinoxalin-2(1H)-ones with N-hydroxyphthalimide esters.

  2020cites this paper
• Visible-light-induced three-component reaction of quinoxalin-2(1H)-ones, alkenes and CF3SO2Na leading to 3-trifluoroalkylated quinoxalin-2(1H)-ones

  2020cites this paper
• Metal-Free Trifluoroalkylation of Quinoxalin-2(1H)-ones with Unactivated Alkenes and Langlois' Reagent.

  2020cites this paper
• Visible-light-promoted acridine red catalyzed aerobic oxidative decarboxylative acylation of α-oxo-carboxylic acids with quinoxalin-2(1H)-ones

  2020cites this paper
• Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine - (thio)urea hybrids as potential kinase inhibitors

  2019cites this paper
• Design and Synthesis of New Quinoxaline Derivatives as Anticancer Agents and Apoptotic Inducers

  2019cites this paper
• Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.

  2019cites this paper
• 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.

  2019cites this paper
• Visible-light-promoted direct C–H/S–H cross-coupling of quinoxalin-2(1H)-ones with thiols leading to 3-sulfenylated quinoxalin-2(1H)-ones in air

  2019cites this paper
• Antitumoral activity of quinoxaline derivatives: A systematic review.

  2019cites this paper
• Design, synthesis and biological evaluation of some novel quinazolinone derivatives as potent apoptotic inducers.

  2018cites this paper
• Synthesis and cytotoxic evaluation of some novel quinoxalinedione diarylamide sorafenib analogues

  2018cites this paper
• Synthèse et étude de l'activité anti-kinétoplastidés de nouvelles 8-nitroquinoléin-2(1H))-ones bioactivées par les nitroréductases de type 1

  2018cites this paper
• Selective Synthesis of Mono- and Disubstituted Quinoxalines via Heteroaromatic Nucleophilic Substitution of 2,3-Dichloro-6,7-dinitroquinoxaline (DCDNQX) with Anilines and Phenols

  2018cites this paper
• Design and synthesis of chemical probes for the BRPF bromodomains

  2017cites this paper
• Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.

  2017cites this paper
• Developing efficient protocols for synthesis, antiosteoarthritic, antiinflammatory assessments and docking studies of nitrogen-containing bisphosphonate derivatives

  2017influential citation
• Quinoxaline‐Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity

  2016cites this paper
• Discovery of 1,3‐Diaryl‐pyridones as Potent VEGFR‐2 Inhibitors: Design, Synthesis, and Biological Evaluation

  2016cites this paper
• Discovery of novel tricyclic pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors.

  2015cites this paper
• Synthesis of a visibly emissive 9-nitro-2,3-dihydro-1H-pyrimido[1,2-a]quinoxalin-5-amine scaffold with large stokes shift and live cell imaging

  2015cites this paper
• Quinoxalines Potential to Target Pathologies.

  2015cites this paper